Recombinant Canis lupus CD19 Protein

重组狗CD19蛋白 | 重组狗CD19分子蛋白

B4 | B-lymphocyte antigen CD19 | B-lymphocyte surface antigen B4 | CD19 antigen | CD19 molecule | CD19 | CVID3 | Differentiation antigen CD19 | Leu-12 | MGC12802 | T-cell surface antigen Leu-12

rp176268-10μg

10μg

无动物源

≥90%(SDS-PAGE)

CD19 protein is a ransmembrane glycoprotein that plays a central role in B cell activation and humoral immune responses. CD19 is expressed throughout B cell development from pre-B cells through mature B cells, and it is commonly used as a B cell lineage marker. It is required for the responsiveness of mature B cell to antigen stimulation, germinal center development, and antibody affinity maturation. The CD19 protein associates with the B cell antigen receptor (BCR), CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu13. These associations enable CD19 to amplify B cell signaling and reduce the threshold for antigen stimulation through the BCR. CD19 polymorphisms and up-regulation can lead to the development of autoimmunity by promoting autoantibody production. CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors. Immunotherapy using a chimeric antigen receptor (CAR) targeting CD19 has proven effective in many different cancers. The first CD19 CAR T cell therapies have been granted FDA approval for the treatment of B cell malignancies with several more in clinical trials. Mature human CD19 protein consists of a 272 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 22 aa transmembrane segment, and a 243 aa cytoplasmic domain. Within the ECD, human CD19 shares 57% amino acid sequence identity with mouse and rat CD19.

重组表达

58.0 kDa

C-hFc & His

68.4-95.7 kDa, under reducing conditions

CHO Accession #: A0A8C0PU30 | CHO

<1.0 EU/μg

狗(Canine)

74-350 aa

MPPPRLLFFLLFLTPMEVRPQETLQVEAKEGGKAELPCLKVPSDGPLEQQAWFQGAQSELGLWSQGLGVRKGSLGIQLFVFNVSDQMGGFYLCQPGPPSEQAWQSGWTVSVEGSGELFRWNASALNDSGCGLGNRPSEGPKPSSRYPTSSQLYVWEKDHPEIWETDPECALPRGTLNQSLNQDLIVAPGSTFWLPCEVPPAFVARGPISWTHVRPKKHNISLLSLDLREDAPGREMWVLGTLSGGAVLLLPQATVRDAGTYRCYHGNRTVEMQLKVIAQSVRYWLLETGGWKVPAVPENLYFQGPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKHHHHHH

Yes

Yes